arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cronos Group Inc.

CRON
$3.71 ▲ +0.20 (+5.70%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
31 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cronos Group Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B
Dividend Yield —
Revenue Growth 58.4% ↗
Op. Margin 14.0% ↗
ROIC 0.7% ↗
FCF / Share $0.06 ↗
Trailing P/E 41.2x
Price / Book 1.3x
FCF Yield 1.6%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$53.01M
↑ +58.4% —
Net Income Profit after all expenses
$32.09M
↑ +133.3% —
Operating Margin Operating profit as % of sales
14.0%
↑ +444.5% 14th
FCF / Share Free cash flow per share
$0.06
↑ +150.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
20
Returns ↑
43
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters